Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sergio Scaccabarozzi"'
Autor:
Americo Cicchetti, Domenico Addesso, Filippo Elvino Leone, Antonino Amato, Luca Angerame, Angelo D'Aversa, Mario Fraticelli, Carlo Nicora, Eleonora Sfreddo, Mariangela Fumarola, Roberta Porcino, Gabriella Cocciolo, Simona Re, Sergio Scaccabarozzi
Publikováno v:
Global & Regional Health Technology Assessment, Vol 7, Iss 1 (2020)
Introduction: From the perspective of healthcare organizations and public health care systems, the value of a clinical trial can be assessed from a clinical and economical perspective. However, to date, there is no standardized model for systematical
Externí odkaz:
https://doaj.org/article/59018222c2794f4bb0680c14fc0af7a3
Autor:
Carlo Pellegrini, Lorenzo Giuliani, Sergio Scaccabarozzi, Hussein Jallous, Eloisa Arbustini, Alexandra Smirnova, Adele Valentini, Mario Urtis, Raffaele Galato, Alessandro Di Toro
Publikováno v:
Journal of the American College of Cardiology. 78:998-999
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5b46fd851f47ffcd3eef7796f8191d6
https://doi.org/10.1016/j.jacc.2021.06.039
https://doi.org/10.1016/j.jacc.2021.06.039
Autor:
Antonino Amato, Luca Angerame, Mariangela Fumarola, Carlo Nicora, Gabriella Cocciolo, Domenico Addesso, Eleonora Sfreddo, Roberta Porcino, Americo Cicchetti, Mario Fraticelli, Sergio Scaccabarozzi, Simona Re, Angelo D'Aversa, Filippo Elvino Leone
Publikováno v:
Global & Regional Health Technology Assessment, Vol 7, Iss 1 (2020)
Introduction: From the perspective of healthcare organizations and public health care systems, the value of a clinical trial can be assessed from a clinical and economical perspective. However, to date, there is no standardized model for systematical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d23839874831e4d8b76beeb57853fc61
https://journals.aboutscience.eu/index.php/grhta/article/view/709
https://journals.aboutscience.eu/index.php/grhta/article/view/709
Autor:
Patrizia Farci, Antonella Mandas, Alessandra Coiana, Maria Eliana Lai, Valeer Desmet, Peter Van Eyken, Yukio Gibo, Luciano Caruso, Sergio Scaccabarozzi, Domenico Criscuolo, Jean-Charles Ryff, Angelo Balestrieri
Publikováno v:
New England Journal of Medicine. 330:88-94
Chronic hepatitis D is a severe and rapidly progressive liver disease for which no therapy has been proved effective. To evaluate the efficacy of treatment with interferon, we studied 42 patients with chronic hepatitis D who were randomly assigned to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6dab88ae4d6d8ee51af2f0df990b2cb
https://doi.org/10.1056/nejm199401133300202
https://doi.org/10.1056/nejm199401133300202
Autor:
Alessandro Tagger, Franco Noventa, Giulio Diodati, Giuseppe Realdi, Federico Tremolada, L. Pollice, Massimo Rugge, Arturo Ruol, C. Casarin, Sergio Scaccabarozzi, P. Bonetti, Cristina Davite
Publikováno v:
Hepatology. 19:1-5
Sixty consecutive patients with chronic hepatitis C were included in a randomized controlled trial of recombinant human interferon-α2a vs. no treatment. Treated patients received tapering doses of interferon thrice weekly for 1 yr. Twenty treated ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a244fda879686a1f67c798e637990a5b
https://doi.org/10.1002/hep.1840190102
https://doi.org/10.1002/hep.1840190102
Autor:
Giuseppe Realdi, Alfredo Alberti, Paula Bonetti, Sergio Scaccabarozzi, Arturo Ruol, C. Casarin, G. Diodati, Claudio Drago
Publikováno v:
Journal of hepatology. 20(3)
Patients treated with alpha-2a interferon for chronic hepatitis C may produce anti-interferon antibodies whose effect, if any, on the individual response to therapy has not been fully clarified. The prevalence and kinetics of anti-interferon, includi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc1538312643ade7e13b3af6551345a0
https://pubmed.ncbi.nlm.nih.gov/7963414
https://pubmed.ncbi.nlm.nih.gov/7963414
A randomized, controlled trial was undertaken to evaluate the response to recombinant interferon alfa-2a in patients with hepatitis B surface antigen negative chronic active hepatitis of unknown aetiology (community-acquired non-A, non-B hepatitis).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7daee089b9b45cb11609340b60f89cc
http://hdl.handle.net/11577/2518239
http://hdl.handle.net/11577/2518239
Autor:
Cristina Barbera, Ferruccio Bonino, Clotilde Iannuzzi, Flavia Bortolotti, Sergio Scaccabarozzi
Publikováno v:
Pediatric Research. 28:298-298
127 TREATMENT OF CHRONIC TYPE B HEPATITIS WITH RECOMBINANT ALPHA 2a INTERFERON IN HBeAg POSITIVE CHILDREN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f968ecdf40c747966d441ea2f1170105
https://doi.org/10.1203/00006450-199009000-00151
https://doi.org/10.1203/00006450-199009000-00151
Autor:
Sergio Scaccabarozzi, Giuseppe Realdi, A. Tagger, Arturo Ruol, C. Diodati, Alessandra Alberti, P. Bonetti
Publikováno v:
Journal of Hepatology. 11:S84
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2389a0ceec9deeec08f19e3c084fd6d
https://doi.org/10.1016/0168-8278(90)91669-n
https://doi.org/10.1016/0168-8278(90)91669-n
Autor:
Saverio Dipalo, Sergio Scaccabarozzi, Giuseppe Gallus, Valerio DiCarlo, M. Cristallo, Giovanni Radaelli, Enrico Fiacco, P. Baccari, Marco Braga
Publikováno v:
JPEN. Journal of parenteral and enteral nutrition. 12(2)
The utilization of delayed hypersensitivity response (DHR) for the identification of high-risk patients with regard to postoperative septic complications is still discussed. The aim of this study was to clarify how much DHR may improve the prognostic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774a2aeb0467e22f4c6ff5dfab7427c7
https://pubmed.ncbi.nlm.nih.gov/3283387
https://pubmed.ncbi.nlm.nih.gov/3283387